Moderna, Inc.
MRNA
$125.59
$14.1312.68%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -63.81% | -57.97% | -55.38% | -36.16% | -0.19% |
| Total Other Revenue | -78.62% | -56.31% | -12.76% | 72.90% | 200.00% |
| Total Revenue | -64.45% | -57.36% | -53.67% | -33.37% | 4.29% |
| Cost of Revenue | 9.49% | 43.86% | 36.06% | 62.27% | 89.04% |
| Gross Profit | -125.49% | -108.52% | -89.07% | -64.76% | -23.88% |
| SG&A Expenses | 36.84% | 51.77% | 52.12% | 54.22% | 99.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.64% | 44.79% | 37.92% | 61.31% | 90.20% |
| Operating Income | -145.00% | -120.11% | -96.72% | -70.31% | -29.15% |
| Income Before Tax | -141.17% | -117.68% | -94.78% | -68.99% | -27.93% |
| Income Tax Expenses | -36.36% | -29.14% | -124.16% | -84.10% | 12.00% |
| Earnings from Continuing Operations | -156.37% | -129.46% | -91.41% | -67.32% | -31.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -156.37% | -129.46% | -91.41% | -67.32% | -31.47% |
| EBIT | -145.00% | -120.11% | -96.72% | -70.31% | -29.15% |
| EBITDA | -137.04% | -115.93% | -94.51% | -68.74% | -27.79% |
| EPS Basic | -158.58% | -131.15% | -91.23% | -66.29% | -30.14% |
| Normalized Basic EPS | -141.87% | -118.28% | -94.64% | -67.74% | -26.37% |
| EPS Diluted | -162.14% | -133.74% | -91.66% | -65.92% | -29.35% |
| Normalized Diluted EPS | -144.17% | -119.96% | -95.25% | -67.41% | -25.52% |
| Average Basic Shares Outstanding | -2.80% | -3.77% | -4.04% | -3.47% | -2.36% |
| Average Diluted Shares Outstanding | -6.02% | -6.87% | -6.26% | -4.70% | -3.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
